Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Chris Lange 24/7 Wall St. has put together a preview of Exxon, Apple, Pfizer and other the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Boeing stock had another solid week, rising by about 3% to bolster its ranking as the best performing Dow stock so far in 2018. One analyst even raised his price target and…
General Electric, Boeing, Merck, and Disney weighed on the DJIA Thursday.
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that…
The top analyst upgrades, downgrades and other research calls from Wednesday include Apple, Cisco, Citigroup, Dollar General, Groupon, IBM, Merck, Ulta Beauty and UnitedHealth.
Tuesday was a crazy day for the U.S. markets, while all three of the major averages hit all-time highs the S&P 500 and Nasdaq closed down on the day. Prior to the…
GE and United Technologies were the big drags on the DJIA Tuesday, while Merck and UnitedHealth kept the index propped up.
Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints.
Chris Lange Boeing, Travelers, Merck, and Microsoft were among leading gainers on the DJIA Friday.
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
